Stem Cell Clinic

Curis Announces Date for the 1st Symposium on IRAK4 in Cancer – PR Newswire

By Stell Cell Research

Symposium hosted by Guillermo Garcia-Manero, M.D.; Hagop Kantarjian, M.D.; Amit Verma, M.B.B.S.

Academics and industry professionals will gather virtually on October 7, 2022

LEXINGTON, Mass., Oct. 3, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the 1st Symposium on IRAK4 in Cancer taking place virtually onOctober 7,9:00am-1:00pm ET.

Hosted by Drs. Guillermo Garcia-Manero, Hagop Kantarjian, and Amit Verma, this symposium will focus on IRAK4, an essential protein in innate immune response and promising target in the treatment of hematologic malignancies and other cancers. Experts across academia and industry will discuss IRAK4 biology, the present understanding of IRAK4 function, and the future of anti-cancer therapeutic development focused on this target.

"Following the success of the VISTA Symposium over the past two years, Curis is proud to be sponsoring the first symposium on IRAK4 in cancer," said James Dentzer, President, and Chief Executive Officer of Curis. "IRAK4 shows great promise as a potential immunotherapy target for the treatment of hematologic cancers, as well as solid tumors, and we look forward to advancing the conversation on how this promise is being translated into meaningful results for patients."

Symposium hosts:

Joining our hosts will be the following speakers and participants:

The virtual event will address topics including:

To learn more about the free to attend symposium and register, please visit https://bit.ly/IRAK4.

AboutCuris, Inc.Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, emavusertib (CA-4948). Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma trial, in patients with hematologic malignancies, such as non-Hodgkin's lymphoma and other B cell malignancies, both as a monotherapy and in combination with BTK inhibitor ibrutinib, and the Phase 1/2 TakeAim Leukemia trial in patients with AML and MDS, for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration. The FDA has placed a partial clinical hold on the TakeAim Leukemia trial during which no new patients will be enrolled in the combination phase (Phase 1b) of emavusertib with azacitidine or venetoclax and expansion phase (Phase 2a), and current study participants benefiting from treatment may continue to be treated with emavusertib at doses of 300mg BID or lower. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1 trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website atwww.curis.com.

SOURCE Curis, Inc.

Read the rest here:
Curis Announces Date for the 1st Symposium on IRAK4 in Cancer - PR Newswire

A Clear Vision | The UCSB Current – The UCSB Current

By Stell Cell Research

Good vision is essential to everyday living, yet approximately 12 million Americans aged 40 and over live with vision impairment, including 1 million who are legally blind, according to the Centers for Disease Control and Prevention. Although some affected individuals can be treated with surgery or medication, and recent advances in gene and stem cell therapies are showing promise, no effective treatments exist for many people who are blinded by severe degeneration of, or damage to, the retina, the optic nerve or the cortex. In such cases, an electronic visual prosthesis, or bionic eye, may be the only option.

Michael Beyeler, an assistant professor of computer science and psychological and brain sciences at UC Santa Barbara, aims to bring to the mainstream an AI-powered bionic eye that can generate artificial vision, in an effort to increase the quality of life for patients who are blind or visually impaired.

I envision a smart bionic eye that could find misplaced keys on a counter, read out medication labels, inform a user about peoples gestures and facial expressions during social interactions, and warn a user of nearby obstacles and outline safe paths, he said.

For his project, Towards a Smart Bionic Eye: AI-Powered Artificial Vision for the Treatment of Incurable Blindness, Beyeler has been selected for a National Institutes of Health (NIH) Directors New Innovator Award. The five-year, $1.5 million grant was one of 103 awarded this week by the NIH to enable exceptionally creative early-career scientists to push the boundaries of biomedical science and pursue high-impact projects that aim to advance knowledge and enhance health.

I offer my sincerest congratulations to Professor Beyeler for having his innovative research recognized with the prestigious NIH Director's New Innovator Award, saidTresa Pollock,the interim dean of the College of Engineering and Alcoa Distinguished Professor of Materials. His novel approach of using recent advances in computer vision, AI and neuroscience has tremendous potential to uncover new knowledge and provide millions of people with useful vision through a smart bionic eye.

I am tremendously honored and excited to be given this award, said Beyeler, who has previously received the NIH Pathway to Independence Award. As part of the NIHs High-Risk, High-Reward Research program, this award will allow my group to explain the science behind bionic technologies that may one day restore useful vision to millions of people living with incurable blindness.

Bionic eyes, as we know them, transform light, captured by a head-mounted camera, into electrical pulses that are delivered through a microelectrode array implanted in the eye or the visual cortex, which is then interpreted by the brain as visual perceptions, or phosphenes. Although current devices generally offer an improved ability to differentiate light from dark backgrounds and see motion, the vision they provide is blurry, distorted and often hard to interpret.

A major challenge for scientists trying to develop visual prosthetics is thus to predict what implant recipients see when they use their devices. Instead of seeing focal spots of light, current retinal-implant users perceive highly distorted phosphenes that often fail to assemble into more complex objects of perception. Consequently, the vision generated by current prostheses has been widely described as fundamentally different from natural vision, and does not improve over time.

Beyeler takes a different approach. Rather than aiming to make bionic vision as natural as possible, he proposes to focus on how to create practical and useful artificial vision that would be based on artificial intelligence (AI)-based scene understanding and be tailored to specific real-world tasks that affect a blind persons quality of life, such as facial recognition, outdoor navigation and self-care.

His novel, multidisciplinary strategy for this project will investigate the neural code of vision, studying how to translate electrode stimulation into a code that the human brain can understand.

We want to address fundamental questions at the intersection of neuroscience, computer science, and human-computer interaction to enable the development of a Smart Bionic Eye, a visual neuroprosthesis that functions as an AI-powered visual aid for the blind, said Beyeler.

To enable a technology that provides cues to the visually impaired, much as a computer vision system talks to a self-driving car, Beyeler must first understand how visual prostheses interact with the human visual system to shape perception. He said that a common misconception in the field is that each electrode in a devices microelectrode array can be thought of as a pixel in an image, or a minute area of illumination on a display screen, and that to generate a complex visual experience, one simply needs to turn on the right combination of pixels. His research shows, however, that the visual experience provided by current prostheses is highly distorted and unrelated to the number of electrodes.

Current devices do not have sufficient image resolution to convey a complex natural scene. Hence, there is a need for scene simplification, Beyeler said.

One way to simplify the visual scene and create useful artificial vision, according to Beyeler, is through deep-learning-based computer vision, which can be used to highlight nearby obstacles or remove background clutter. Computer vision is a field of AI that enables computers and systems to derive important information from digital images, videos and other visual inputs and take actions or make recommendations based on that information. Computer vision relies on cameras, data, and algorithms, rather than retinas, optic nerves and a visual cortex.

He said that his project will be patient-centric, involving people at all stages of the design process to test out his groups theoretical predictions. The patients will be provided by his collaborators at four universities across the country and in Spain. Beyelers team will design experiments that probe an implants potential to support functional vision for real-world tasks involving object recognition, scene understanding and mobility. This method strays from the typical vision tests performed in clinics that measure acuity, contrast sensitivity and orientation discrimination.

Due to the unique requirements of working with bionic-eye recipients, such as constant assistance, setup time and travel, experimentation remains time-consuming and expensive. Beyeler proposes an interim solution.

A more cost-effective and increasingly popular alternative might be to rely on an immersive virtual reality (VR) prototype based on simulated prosthetic vision (SPV), Beyeler explained.

The classical SPV method relies on sighted subjects wearing a VR head-mounted display (HMD). The subjects are then deprived of natural viewing and allowed to perceive only phosphenes displayed in the HMD. This approach enables sighted participants to see through the eyes of the bionic-eye user as they explore a virtual environment. The visual scene can then be manipulated by researchers according to any desired image-processing or visual-enhancement strategy.

The challenge in the field is less about dreaming up new augmentation strategies and more about finding effective visual representations to support practical, everyday tasks, said Beyeler. This is why, in my project, we utilize a prototyping system that allows us to explore different strategies and find out what works before implanting devices in patients.

In the future, he said, the Smart Bionic Eye could be combined with GPS to give directions, warn users of impending dangers in their immediate surroundings, or even extend the range of visible light with the use of an infrared sensor, providing what he describes as bionic night-time vision. But before any of that can happen, Beyeler said, the fundamental scientific questions must be addressed.

Success of this project would translate to a new potential treatment option for incurable blindness, which affects nearly 40 million people worldwide, said Beyeler, who plans to make all of his groups software, tools and deidentified data available to the scientific community. Overall, this will be a fantastic opportunity for my lab to contribute substantially in the field of sight restoration and make a difference in the world.

See original here:
A Clear Vision | The UCSB Current - The UCSB Current

Global Cell Separation Technology Market Remarkable Growth Factors, New Innovations and Forecast Till 2028- Zi – openPR

By Stell Cell Research

Global Point Of Care Diagnostics Market

Major parameters covered under these company profiles include revenues, gross profits, operating income, COGS, EBITDA, sales volume, product offerings, company landscape analysis, key strategic moves, key recent developments, and technological roadmap. We provides a complete understanding of general market scenarios and future market situations to prepare for rising above the challenges and ensuring strong growth, the complete analysis of Cell Separation Technology Market Size, Data and development forecast from 2022-2028.

Also, representing the Cell Separation Technology Market Factor Analysis- Porter's Five Forces, Supply/Value Chain, PESTEL analysis, CAGR value, product offerings, company landscape analysis, Market Entropy, CAPEX cycle, COGS Analysis, EBITDA analysis, Patent/Trademark Analysis, and Post COVID Impact Analysis. Key Leading Players having extreme Growth Rate in last Few decades included Carl Zeiss AG, Lumenis Ltd, FEI Company, Hamamatsu Photonics K.K, Becton, Dickinson and Company, Perkinelmer, Andor Technology Ltd, Affymetrix Inc, Olympus Corporation of the Americas.

Download FREE Sample Report here:- https://www.zionmarketresearch.com/sample/cell-separation-technologies-market

(We Provide Free Sample copy as per your Research Requirement, also including COVID 19 impact analysis)

Don't miss out on the Analysis of business opportunities in the Cell Separation Technology Market. Speak to our analysts and gain vital industry insights that will help you for your business growth.

The Major Manufactures covered in this Report:- Carl Zeiss AG, Lumenis Ltd, FEI Company, Hamamatsu Photonics K.K, Becton, Dickinson and Company, Perkinelmer, Andor Technology Ltd, Affymetrix Inc, Olympus Corporation of the Americas.

Global Cell Separation Technology Market Product and Application Are:-

Product: Immunomagnetic Cell Separation, Fluorescence-Activated Cell Sorting, Density Gradient Centrifugation, Microfluidic Cell Separation, And Others

Application: Stem Cell Research, Immunology, Neuroscience, Cancer Research, And Others

Our analysts covers all key parameters required for COVID-19 effect on business industry, economic implications their trends, factors, consumer behavior on shopping, effect on spending lot of money on advertising and also on useful industries like medical, transportation, food and Beverage. The globally rising of Bio crisis 'COVID-19' has many businesses are struggling and confused on what steps to take to minimize or maximize the economic impact.

The Global Cell Separation Technology Market Research Report Forecast 2022-2028 is a valuable source of insightful data for business strategists. It provides the Cell Separation Technology industry overview with growth analysis, historical & futuristic cost, revenue, demand and supply data. The research analysts provide an elaborate description of the value chain and its distributor analysis. This Cell Separation Technology market study provides comprehensive data which enhances the understanding scope and application of this report.

Geographically, Global Cell Separation Technology Market covers:- United States, Europe, China, Japan, India and Southeast Asia and rest of the world

(Our Analyst can add Regional analysis as per your Research need also)

Buy This Report: https://www.zionmarketresearch.com/buynow/su/cell-separation-technologies-market

Timeline for Analysis:-

History Year: 2016- 2020 Base Year: 2021 Forecast Year: 2022 to 2028

Key Stakeholders

Cell Separation Technology Manufacturers Cell Separation Technology Distributors/Traders/Wholesalers Cell Separation Technology Subcomponent Manufacturers Industry Association Downstream Vendors

Key questions answered in this report

What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors?

The study objectives of this report are:-

To analyze the opportunities in the market for stakeholders by identifying the high growth segments. To strategically analyze each submarket with respect to individual growth trend and their contribution to the market To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market. To analyze and study the Cell Separation Technology capacity, production, value, consumption and forecast (2022-2028) Focuses on the global key manufacturers to describe and analyze the market competition landscape with SWOT analysis. To define, describe and forecast the market by type, application and region. To analyze the global key regions market potential and advantages, opportunities, challenges, restraints and risks. To identify significant trends and factors driving or inhibiting the market growth. To strategically profile the key players and comprehensively analyze their growth strategies.

View Customized Full Report Related News with TOC @ https://bit.ly/3fzdZgB

If you have any special requirements, please let us know and we will offer you the report as you want.

Read Our Other Reports:

Global Point Of Care Diagnostics Market Key Drivers, Size & Share 2022-2028 Report by Zion Market Research: https://www.openpr.com/news/2757927/global-point-of-care-diagnostics-market-key-drivers-size-share

Global Personal Care Appliances Market: https://www.einnews.com/pr_news/593358124/global-personal-care-appliances-market-growth-increasing-more-than-usd-29-25-billion-by-2028-says-zion-market-research

Global Space Situational Awareness (SSA) Market: https://www.einnews.com/pr_news/593198972/at-cagr-4-6-global-space-situational-awareness-ssa-market-expected-to-reach-approximately-usd-1-495-million-by-2027

Reach Out us at the following address:

Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States Tel: +1 (844) 845-5245 Email: sales@zionmarketresearch.com

Our Expertise

In Zion Market Research, we have built our team with industry analysts, domain experts, and consultants, who leverage their global experience that help us deliver excellence in all projects we undertake. Zion Market Research publishes over 100+ market research reports that provide data covering following aspects:

Market Research Market Sizing and Forecasts Industry Entry Strategies Niche Market Trends Novel Sustainability Trends Innovation Trends Customer Cognizance Distribution Channel Assessment Primary Interviews Consumer Surveys Secondary Research

This release was published on openPR.

Continue reading here:
Global Cell Separation Technology Market Remarkable Growth Factors, New Innovations and Forecast Till 2028- Zi - openPR

Nancy and Geoffrey Stack Family Foundation give $2 million to UCI Health – UCI News

By Stell Cell Research

Oct. 3, 2022, Irvine, Calif. UCI Health is pleased to announce a $2 million gift that will benefit the emergency department in the new $1.3 billion UCI Health Irvine medical campus being built on the corner of Jamboree Road and Birch Street in Irvine.

The gift, funded by the Nancy and Geoffrey Stack Family Foundation, will name the patient welcome areas in the emergency department of the planned acute care hospital and at the Chao Family Comprehensive Cancer Care and Ambulatory Care building.

UCI Health is grateful for the friendship and generosity of Nancy and Geoffrey Stack, said UCI Health CEO Chad Lefteris. With their support, we continue to improve access to the clinical innovation, lifesaving research, and world class care of Orange Countys only academic health system.

In November, UCI and the universitys health enterprise, UCI Health, officially broke ground on the medical complex, which will include a 144-bed general acute care hospital with an emergency department, the Chao Family Comprehensive Cancer Center and Ambulatory Care center and the Joe C. Wen & Family Center for Advanced Care.

The UCI Health Irvine complex will support the systems growing primary and specialty care network in coastal and south Orange County, Lefteris said.

UCI Health is a beacon of hope in Orange County, said Nancy Stack. The new medical complex will bring hope and healing to our region and will save lives. Jeff and I are honored to support such a worthwhile cause.

The Stacks are longtime supporters of UCI Health. The couple has made previous philanthropic gifts to support UCI Medical Center in Orange. They have continued their legacy of giving by investing in healthcare through the UCI Health Irvine medical campus.

The new UCI Health Irvine medical campus will complement the UCI Medical Center in Orange and will be a key part to providing the region with the advanced care available only from a health system that is part of a leading, premier academic research institution. The hospital will include a 24-hour emergency department and focus on leading clinical programs including oncology, neurology, neurosurgery, orthopedics, and digestive health. The first patients are expected in 2023 at the Joe. C. Wen & Family Center for Advanced Care. The Chao Family Comprehensive Cancer Care and Ambulatory Care building, and the hospital will begin serving patients in 2023 and 2025, respectively.

Nancy and Geoffrey Stack Family Foundation was created by the longtime Orange County residents to support education, health and other vital community-based programs in Orange County and beyond. Geoffrey Stack is one of the founding partners of the Sares-Regis Group, a commercial and residential real estate development and management firm. Nancy Stack is founder and president of the Cystinosis Research Foundation, which supports medical research including stem cell research seeking a cure for the rare disease cystinosis.

If you want to learn more about supporting this or other activities at UCI, please visit the Brilliant Future website athttps://brilliantfuture.uci.edu. Publicly launched on Oct. 4, 2019, the Brilliant Future campaign aims to raise awareness and support for UCI. By engaging 75,000 alumni and garnering $2 billion in philanthropic investment, UCI seeks to reach new heights of excellence instudent success,health and wellness, research and more. UCI Health plays a vital role in the success of the campaign. Learn more by visiting https://brilliantfuture.uci.edu/uci-health/

About UCI Health:UCI Healthis the clinical enterprise of the University of California, Irvine. Patients can access UCI Health at primary and specialty care offices across Orange County and at its main campus,UCI Medical Center in Orange, Calif. The 459-bed acute-care hospital, listed among Americas Best Hospitals byU.S. News & World Reportfor 22 consecutive years, provides tertiary and quaternary care, ambulatory and specialty medical clinics, as well as behavioral health and rehabilitation services. UCI Medical Center is home to Orange Countys onlyNational Cancer Institute-designated comprehensive cancer center,high-risk perinatal/neonatal programandAmerican College of Surgeons-verified Level I adult and Level II pediatric trauma centerandregional burn center. It is the primary teaching hospital for theUCI School of Medicine. UCI Health serves a region of nearly 4 million people in Orange County, western Riverside County and southeast Los Angeles County. Follow us onFacebookandTwitter.

About the University of California, Irvine:Founded in 1965, UCI is the youngest member of the prestigious Association of American Universities and is ranked among the nations top 10 public universities byU.S. News & World Report. The campus has produced three Nobel laureates and is known for its academic achievement, premier research, innovation and anteater mascot. Led by Chancellor Howard Gillman, UCI has more than 36,000 students and offers 224 degree programs. Its located in one of the worlds safest and most economically vibrant communities and is Orange Countys second-largest employer, contributing $7 billion annually to the local economy and $8 billion statewide. For more on UCI, visitwww.uci.edu.

Excerpt from:
Nancy and Geoffrey Stack Family Foundation give $2 million to UCI Health - UCI News

Promaxo Announces Six System Sales in the Third Quarter 2022 – The Bakersfield Californian

By Stem Cell Clinics

OAKLAND, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Promaxo, Inc. (Promaxo or the Company), a medical imaging, robotics, and AI technology company, today announced the sale of six systems in the United States in the third quarter ending September 30, 2022. The system sales included both operating lease and revenue share agreements with physician practices in Florida, New Jersey, and Texas. Promaxos single-sided MRI with AI based imaging system, FDA cleared for in-office use, empowers practices and hospitals to accurately and seamlessly guide prostate interventions under the Promaxo MRI system.

In the third quarter, North Florida Urology Associates in Gainesville, FL, Avant Concierge Urology in Winter Garden, FL, Urology Center of Winter Park in Winter Park, FL, Sovereign Health System in Jersey City, NJ, Jersey Urology Group in Somers Point, NJ, and Urology America MSO in Austin, TX entered into agreements with Promaxo.

Dr. Sijo Parekattil, Director of Avant Concierge Urology and Associate Professor of Urology at the University of Central Florida said, Given our focus on leveraging the latest technologies, robotics and microsurgery in our urology practice, incorporating the Promaxo MRI system into our programs was a natural and synergistic next step. Coupled with the flexibility of commercial partnership programs offered by Promaxo, we are impressed with the ease at which we place the system in our office and with how quickly we begin to provide Promaxo MRI procedures to our patients.

With focused market penetration activities, we are pleased to add six new physician practices to Promaxos growing clinical network in the United States, maintaining our growth momentum through the third quarter 2022, said Dr. Amit Vohra, Founder and CEO of Promaxo. We are committed to making MRIs more accessible for interventions, as we continue to partner with physician offices through our flexible sales and financing programs.

About Sovereign Health System

Sovereign Health System is a multi-specialty community healthcare system, with primary and specialty medical care provided by the physicians of the Sovereign Health Medical Group, in addition to outpatient care provided by Sovereign Health Urgent Care, Sovereign Health Cancer Care, and Sovereign Health SurgiCare. Sovereign Health Medical Group has ten urology practice locations in New Jersey.

About North Florida Urology Associates

North Florida Urology Associates is a medical practice with clinics in Ocala, Gainesville, and The Villages, Florida. With a focus on promoting mens health for over 36 years, the practice has raised awareness and led its field in treating conditions such as prostate cancer, erectile dysfunction, and kidney stones by leveraging leading technologies. The practice utilizes technologies such as HIFU, ErosWave, cryosurgery, shockwave therapy, and stem cell therapy to address and treat their patients needs.

About Avant Concierge Urology

Avant Concierge Urology is a Central Florida urology practice, specializing in the treatment of conditions related to the kidneys, urinary bladder, adrenal glands, urethra, and male reproductive organs. Avant offers personalized, best-in-class surgical treatment options, with the intent to minimize downtime, scarring, and expenses. With focus on offering latest technologies, including digital microsurgery, Avant is the first and only in-office operator of the Karl STORZ 3D Vitom digital microsurgery system in the United States, offering patients a best-in-class surgery solution allowing for better precision and decreased recovery time.

About Jersey Urology Group

Jersey Urology Group is a comprehensive urology practice in southern New Jersey, with a team of top urology doctors in New Jersey offering patients state-of-the-art technologies and innovative therapies for the treatment of all urologic conditions. Urology services include treating kidney stones, prostate problems, infertility, and other complex urological issues.

About Urology Center of Winter Park

Urology Center of Winter Park, centrally located in Florida at Winter Park, utilizes state of the art, minimally invasive urological procedures in the diagnosis and treatment of all types of urological issues. The practice provides medical solutions dedicated to all aspects of urological care with the latest in minimally, and non-invasive techniques to reduce pain and hasten recovery. Services include urology, urologic surgery and urologic oncology.

About Urology America MSO

Urology America is a national, best-in-class urology platform founded in Central Texas by Urology Austin physicians and Gauge Capital. Urology Americas mission is to build a platform that provides unparalleled support to providers and care team, to deliver exceptional and comprehensive urological care, with compassion and service that exceeds expectations. Urology America is built with a focus on achieving returns through innovation and revenue growth. This includes drawing on expertise and collective experience to develop new services where applicable.

About Promaxo, Inc.

Promaxo was founded by a team of entrepreneurs and healthcare innovators to develop a minimally-invasive and patient-centric MRI and robotic platform. Based in Oakland, California, and backed by over 200 patents, the Companys mission is to improve lives through state-of-the-art medical imaging, robotics and AI capabilities. With a compact and adaptable MRI, Promaxo is redefining the standard of care by improving the quality and speed of patient diagnosis and interventions. The Company has formed numerous long-term and strategic partnerships with investor groups and corporation as it drives commercialization of the Promaxo MRI system.

To learn more about the technology behind the MRI system and its scope, please visit: Promaxo.com.

LinkedIn: Promaxo

Twitter: @Promaxo

Facebook: Promaxo

Investors

Gilmartin Group

Vivian Cervantes

e: IR@promaxo.com

Link:
Promaxo Announces Six System Sales in the Third Quarter 2022 - The Bakersfield Californian

Announcement of Training in Fort Lauderdale, Florida by The Global Stem Cells Group – Digital Journal

By Stem Cell Medicine

Recently, the Global Stem Cells Group announced plans to teach physicians the value and process behind incorporating regenerative medicine into their own clinical practices.

MIAMI 4 Octocber, 2022 Global Stem Cells Group, a multidisciplinary community of scientists and physicians that are working together to cure diseases and relieve human pain through the advancement of the field of regenerative medicine, announced today a plan of training in Fort Lauderdale on November 4th and 5th. This training aims to equip physicians with the value and knowledge behind incorporating regenerative medicine into their own clinical practice.Benito Novas, CEO of GSCG,is confident that the event will bring together a group of:

i. Doctors are seeking training, products, and equipment in regenerative medicine.

ii. Doctors who care for patients with conditions that can be treated with cell therapies

iii. Aesthetic doctors.

iv. Doctors who want to be up to date with the latest technologies and protocols

v. Doctors with an interest in new research on stem cells, MSC, Exosomes, and medical networks want to attract more clients.

The training course is intended to cover:

Hands-On portion:Doctors, in a controlled environment and guided by a team of medical professionals, will have the opportunity to see procedures being performed a few feet away and then get the opportunity to try them for themselves.

Review of stem cell biology

Characterization of cells, cell products, cytokines, and growth factors, as well as their capacity for regeneration.

Laboratory Processes

Clinical applications

Product validation

Practice Management

Patient acquisition

TheInternational Society for Stem Cell Application (ISSCA)has done intensive research on this topic and the team will take a lead in educating, training, and certification during the event. As a medical speciality, regenerative standards and certification are very important, which is why ISSCA will provide certificates after the training. By the end of the training course, you will understand everything you need to know to add adult stem cellbased procedures to your existing practice. As before, the united efforts of the seven major medical corporations will provide practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

To find more about the courses and to make reservations for this particular event, head on to their website http://www.issca.us/autologous-miami-november/ .us email [emailprotected] or dial +1305 560 5337.

AboutISSCA

ISSCA is a multidisciplinary community that brings together scientists and physicians, all of whom aspire to treat diseases and relieve human pain through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through innovations made to the speciality of regenerative medicine. The ISSCAs vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, training, research, education, and certification.

As a medical speciality, regenerative medicine standards and certifications are very important, which is why ISSCA provides certification training globally. This is because they want to encourage more physicians to practice regenerative medicine and make it accessible to benefit patients both nationally and worldwide. Incorporated under the Republic of Korea as a nonprofit entity, the ISSCAs main goal is to promote excellence and standards in the field of regenerative medicine. As a physician, missing this chance to book a personalized hands-on training session must cost you dearly. Contact +1 305 560 5337 to book as early as possible.

AboutGlobal Stem Cells Group

Global Stem Cells Group is the parent company of six companies that are dedicated to stem cell research, solutions, and technology training. The group was founded in 2012 and combines dedicated researchers, patient educators, and physician trainers with the shared goal of meeting the need for high-end stem cell solutions and treatments.

Given that the group has a singular focus in this field, it is uniquely positioned to become the global leader in cellular medicine. In addition, by bringing together leading professionals in cellular medicine, it can discover issues that the industry faces and focus its research and development in this area. This specialization has, undoubtedly, enabled it to come up with solutions that address some of the significant issues that most stakeholders are facing in the industry.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV.https://finance.yahoo.com/quote/mssv/

Media Contact Company Name: Global Stem Cells Group Contact Person: Benito Novas Email: Send Email Phone: (305) 560-5337 Address:Datran Center 9100 S Dadeland Boulevard, Suite 1500 City: Miami State: Fl 33156 Country: United States Website: https://www.stemcellsgroup.com/

Continued here:
Announcement of Training in Fort Lauderdale, Florida by The Global Stem Cells Group - Digital Journal

Stem Cell Therapy Market with 8.18% CAGR : Industry Analysis By Future Demand, Top Players, Revenue and Growth Rate Through 2027 | 112 Report Pages -…

By Stem Cell Medicine

The size of the global Stem Cell Therapy market was estimated to be USD 11910.63 in 2021 and to increase to USD 19090.47 by 2028, with a forecasted CAGR of 8.18%. The majority of companies [Pharmicell Co., Ltd, MEDIPOST Co., Ltd., Nuvasive, Inc., RTI Surgical, Inc., Holostem Terapie Avanzate S.r.l., Cytori Therapeutics, Fibrocell Science, Inc., Osiris Therapeutics, Inc., Promethera Biosciences, RTI Surgical, Inc, Celgene Corporation, Anterogen Co., Ltd.] discussed in the report have focused on expansion, investment, acquisitions, delivery focus, portfolio expansion, and brand development.

Stem Cell Therapy Market Insights 2022 By Types (Adult Stem Cells, Human Embryonic, Induced Pluripotent Stem Cells, Very Small Embryonic Like Stem Cells), Applications (Regenerative Medicine, Drug Discovery and Development), By Segmentation, Regions and Forecast to 2028. The Global Stem Cell Therapy market Report provides In-depth analysis on the market status of the Stem Cell Therapy Top manufacturers with best facts and figures, meaning, Definition, SWOT and PESTAL analysis, expert opinions and the latest developments across the globe., the Stem Cell Therapy Market Report contains Full TOC, Tables and Figures, and Chart with Key Analysis, Pre and Post COVID-19 Market Outbreak Impact Analysis and Situation by Regions.

Stem Cell Therapy Market Research Report is spread across 112 Pages and provides exclusive data, information, vital statistics, trends, and competitive landscape details in this niche sector.

The global Stem Cell Therapy market size was valued at USD 11910.63 million in 2021 and is expected to expand at a CAGR of 8.18% during the forecast period, reaching USD 19090.47 million by 2027.

Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition.Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use. Research is underway to develop various sources for stem cells, and to apply stem-cell treatments for neurodegenerative diseases and conditions, diabetes, heart disease, and other conditions.With the ability of scientists to isolate and culture embryonic stem cells, and with scientists growing ability to create stem cells using somatic cell nuclear transfer and techniques to create induced pluripotent stem cells, controversy has crept in, both related to abortion politics and to human cloning. Additionally, efforts to market treatments based on transplant of stored umbilical cord blood have been controversial.

The report combines extensive quantitative analysis and exhaustive qualitative analysis, ranges from a macro overview of the total market size, industry chain, and market dynamics to micro details of segment markets by type, application and region, and, as a result, provides a holistic view of, as well as a deep insight into the Stem Cell Therapy market covering all its essential aspects.

For the competitive landscape, the report also introduces players in the industry from the perspective of the market share, concentration ratio, etc., and describes the leading companies in detail, with which the readers can get a better idea of their competitors and acquire an in-depth understanding of the competitive situation. Further, mergers and acquisitions, emerging market trends, the impact of COVID-19, and regional conflicts will all be considered.

In a nutshell, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the market in any manner.

The Global Stem Cell Therapy market is anticipated to rise at a considerable rate during the forecast period, between 2022 and 2028. In 2021, the market is growing at a steady rate and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Final Report will add the analysis of the impact of COVID-19 And Russia Ukraine War on this industry.

TO KNOW HOW COVID-19 PANDEMIC AND RUSSIA UKRAINE WAR WILL IMPACT THIS MARKET REQUEST SAMPLE

Moreover, it helps new businesses perform a positive assessment of their business plans because it covers a range of topics market participants must be aware of to remain competitive.

Stem Cell Therapy Market Report identifies various key players in the market and sheds light on their strategies and collaborations to combat competition. The comprehensive report provides a two-dimensional picture of the market. By knowing the global revenue of manufacturers, the global price of manufacturers, and the production by manufacturers during the forecast period of 2022 to 2028, the reader can identify the footprints of manufacturers in the Stem Cell Therapy industry.

Get a Sample PDF of report https://www.360researchreports.com/enquiry/request-sample/21612397

As well as providing an overview of successful marketing strategies, market contributions, and recent developments of leading companies, the report also offers a dashboard overview of leading companies past and present performance. Several methodologies and analyses are used in the research report to provide in-depth and accurate information about the Stem Cell Therapy Market.

Which are the prominent Stem Cell Therapy Market players across the globe?

The current market dossier provides market growth potential, opportunities, drivers, industry-specific challenges and risks market share along with the growth rate of the global Stem Cell Therapy market. The report also covers monetary and exchange fluctuations, import-export trade, and global market

status in a smooth-tongued pattern. The SWOT analysis, compiled by industry experts, Industry Concentration Ratio and the latest developments for the global Stem Cell Therapy market share are covered in a statistical way in the form of tables and figures including graphs and charts for easy understanding.

Get a Sample Copy of the Stem Cell Therapy Market Report 2022

A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market experts opinions have been taken to understand the market better.

Report further studies the market development status and future Stem Cell Therapy Market trend across the world. Also, it splits Stem Cell Therapy market Segmentation by Type and by Applications to fully and deeply research and reveal market profile and prospects.

On the basis of product type this report displays the production, revenue, price, market share and growth rate of each type, primarily split into:

On the basis of the end users/applications this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including:

Stem Cell Therapy Market Regional Analysis:

Which region is expected to hold the highest market share in the Stem Cell Therapy Market?

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Stem Cell Therapy in these regions, from 2015 to 2027, covering

This Stem Cell Therapy Market Research/Analysis Report Contains Answers to your following Questions

Our research analysts will help you to get customized details for your report, which can be modified in terms of a specific region, application or any statistical details. In addition, we are always willing to comply with the study, which triangulated with your own data to make the market research more comprehensive in your perspective.

Inquire more and share questions if any before the purchase on this report at https://www.360researchreports.com/enquiry/pre-order-enquiry/21612397

With tables and figures helping analyse worldwide Global Stem Cell Therapy market trends, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Table of Content

1 Stem Cell Therapy Market Overview 1.1 Product Overview and Scope of Stem Cell Therapy Market 1.2 Stem Cell Therapy Market Segment by Type 1.2.1 Global Stem Cell Therapy Market Sales Volume and CAGR (%) Comparison by Type (2017-2027) 1.3 Global Stem Cell Therapy Market Segment by Application 1.3.1 Stem Cell Therapy Market Consumption (Sales Volume) Comparison by Application (2017-2027) 1.4 Global Stem Cell Therapy Market, Region Wise (2017-2027) 1.4.1 Global Stem Cell Therapy Market Size (Revenue) and CAGR (%) Comparison by Region (2017-2027) 1.4.2 United States Stem Cell Therapy Market Status and Prospect (2017-2027) 1.4.3 Europe Stem Cell Therapy Market Status and Prospect (2017-2027) 1.4.4 China Stem Cell Therapy Market Status and Prospect (2017-2027) 1.4.5 Japan Stem Cell Therapy Market Status and Prospect (2017-2027) 1.4.6 India Stem Cell Therapy Market Status and Prospect (2017-2027) 1.4.7 Southeast Asia Stem Cell Therapy Market Status and Prospect (2017-2027) 1.4.8 Latin America Stem Cell Therapy Market Status and Prospect (2017-2027) 1.4.9 Middle East and Africa Stem Cell Therapy Market Status and Prospect (2017-2027) 1.5 Global Market Size of Stem Cell Therapy (2017-2027) 1.5.1 Global Stem Cell Therapy Market Revenue Status and Outlook (2017-2027) 1.5.2 Global Stem Cell Therapy Market Sales Volume Status and Outlook (2017-2027) 1.6 Global Macroeconomic Analysis 1.7 The impact of the Russia-Ukraine war on the Stem Cell Therapy Market

2 Industry Outlook 2.1 Stem Cell Therapy Industry Technology Status and Trends 2.2 Industry Entry Barriers 2.2.1 Analysis of Financial Barriers 2.2.2 Analysis of Technical Barriers 2.2.3 Analysis of Talent Barriers 2.2.4 Analysis of Brand Barrier 2.3 Stem Cell Therapy Market Drivers Analysis 2.4 Stem Cell Therapy Market Challenges Analysis 2.5 Emerging Market Trends 2.6 Consumer Preference Analysis 2.7 Stem Cell Therapy Industry Development Trends under COVID-19 Outbreak 2.7.1 Global COVID-19 Status Overview 2.7.2 Influence of COVID-19 Outbreak on Stem Cell Therapy Industry Development

3 Global Stem Cell Therapy Market Landscape by Player 3.1 Global Stem Cell Therapy Sales Volume and Share by Player (2017-2022) 3.2 Global Stem Cell Therapy Revenue and Market Share by Player (2017-2022) 3.3 Global Stem Cell Therapy Average Price by Player (2017-2022) 3.4 Global Stem Cell Therapy Gross Margin by Player (2017-2022) 3.5 Stem Cell Therapy Market Competitive Situation and Trends 3.5.1 Stem Cell Therapy Market Concentration Rate 3.5.2 Stem Cell Therapy Market Share of Top 3 and Top 6 Players 3.5.3 Mergers and Acquisitions, Expansion

4 Global Stem Cell Therapy Sales Volume and Revenue Region Wise (2017-2022) 4.1 Global Stem Cell Therapy Sales Volume and Market Share, Region Wise (2017-2022) 4.2 Global Stem Cell Therapy Revenue and Market Share, Region Wise (2017-2022) 4.3 Global Stem Cell Therapy Sales Volume, Revenue, Price and Gross Margin (2017-2022) 4.4 United States Stem Cell Therapy Sales Volume, Revenue, Price and Gross Margin (2017-2022) 4.4.1 United States Stem Cell Therapy Market Under COVID-19 4.5 Europe Stem Cell Therapy Sales Volume, Revenue, Price and Gross Margin (2017-2022) 4.5.1 Europe Stem Cell Therapy Market Under COVID-19 4.6 China Stem Cell Therapy Sales Volume, Revenue, Price and Gross Margin (2017-2022) 4.6.1 China Stem Cell Therapy Market Under COVID-19 4.7 Japan Stem Cell Therapy Sales Volume, Revenue, Price and Gross Margin (2017-2022) 4.7.1 Japan Stem Cell Therapy Market Under COVID-19 4.8 India Stem Cell Therapy Sales Volume, Revenue, Price and Gross Margin (2017-2022) 4.8.1 India Stem Cell Therapy Market Under COVID-19 4.9 Southeast Asia Stem Cell Therapy Sales Volume, Revenue, Price and Gross Margin (2017-2022) 4.9.1 Southeast Asia Stem Cell Therapy Market Under COVID-19 4.10 Latin America Stem Cell Therapy Sales Volume, Revenue, Price and Gross Margin (2017-2022) 4.10.1 Latin America Stem Cell Therapy Market Under COVID-19 4.11 Middle East and Africa Stem Cell Therapy Sales Volume, Revenue, Price and Gross Margin (2017-2022) 4.11.1 Middle East and Africa Stem Cell Therapy Market Under COVID-19

5 Global Stem Cell Therapy Sales Volume, Revenue, Price Trend by Type 5.1 Global Stem Cell Therapy Sales Volume and Market Share by Type (2017-2022) 5.2 Global Stem Cell Therapy Revenue and Market Share by Type (2017-2022) 5.3 Global Stem Cell Therapy Price by Type (2017-2022) 5.4 Global Stem Cell Therapy Sales Volume, Revenue and Growth Rate by Type (2017-2022) 5.4.1 Global Stem Cell Therapy Sales Volume, Revenue and Growth Rate of Adult Stem Cells (2017-2022) 5.4.2 Global Stem Cell Therapy Sales Volume, Revenue and Growth Rate of Human Embryonic (2017-2022) 5.4.3 Global Stem Cell Therapy Sales Volume, Revenue and Growth Rate of Induced Pluripotent Stem Cells (2017-2022) 5.4.4 Global Stem Cell Therapy Sales Volume, Revenue and Growth Rate of Very Small Embryonic Like Stem Cells (2017-2022)

6 Global Stem Cell Therapy Market Analysis by Application 6.1 Global Stem Cell Therapy Consumption and Market Share by Application (2017-2022) 6.2 Global Stem Cell Therapy Consumption Revenue and Market Share by Application (2017-2022) 6.3 Global Stem Cell Therapy Consumption and Growth Rate by Application (2017-2022) 6.3.1 Global Stem Cell Therapy Consumption and Growth Rate of Regenerative Medicine (2017-2022) 6.3.2 Global Stem Cell Therapy Consumption and Growth Rate of Drug Discovery and Development (2017-2022)

7 Global Stem Cell Therapy Market Forecast (2022-2027) 7.1 Global Stem Cell Therapy Sales Volume, Revenue Forecast (2022-2027) 7.1.1 Global Stem Cell Therapy Sales Volume and Growth Rate Forecast (2022-2027) 7.1.2 Global Stem Cell Therapy Revenue and Growth Rate Forecast (2022-2027) 7.1.3 Global Stem Cell Therapy Price and Trend Forecast (2022-2027) 7.2 Global Stem Cell Therapy Sales Volume and Revenue Forecast, Region Wise (2022-2027) 7.2.1 United States Stem Cell Therapy Sales Volume and Revenue Forecast (2022-2027) 7.2.2 Europe Stem Cell Therapy Sales Volume and Revenue Forecast (2022-2027) 7.2.3 China Stem Cell Therapy Sales Volume and Revenue Forecast (2022-2027) 7.2.4 Japan Stem Cell Therapy Sales Volume and Revenue Forecast (2022-2027) 7.2.5 India Stem Cell Therapy Sales Volume and Revenue Forecast (2022-2027) 7.2.6 Southeast Asia Stem Cell Therapy Sales Volume and Revenue Forecast (2022-2027) 7.2.7 Latin America Stem Cell Therapy Sales Volume and Revenue Forecast (2022-2027) 7.2.8 Middle East and Africa Stem Cell Therapy Sales Volume and Revenue Forecast (2022-2027) 7.3 Global Stem Cell Therapy Sales Volume, Revenue and Price Forecast by Type (2022-2027) 7.3.1 Global Stem Cell Therapy Revenue and Growth Rate of Adult Stem Cells (2022-2027) 7.3.2 Global Stem Cell Therapy Revenue and Growth Rate of Human Embryonic (2022-2027) 7.3.3 Global Stem Cell Therapy Revenue and Growth Rate of Induced Pluripotent Stem Cells (2022-2027) 7.3.4 Global Stem Cell Therapy Revenue and Growth Rate of Very Small Embryonic Like Stem Cells (2022-2027) 7.4 Global Stem Cell Therapy Consumption Forecast by Application (2022-2027) 7.4.1 Global Stem Cell Therapy Consumption Value and Growth Rate of Regenerative Medicine(2022-2027) 7.4.2 Global Stem Cell Therapy Consumption Value and Growth Rate of Drug Discovery and Development(2022-2027) 7.5 Stem Cell Therapy Market Forecast Under COVID-19

8 Stem Cell Therapy Market Upstream and Downstream Analysis 8.1 Stem Cell Therapy Industrial Chain Analysis 8.2 Key Raw Materials Suppliers and Price Analysis 8.3 Manufacturing Cost Structure Analysis 8.3.1 Labor Cost Analysis 8.3.2 Energy Costs Analysis 8.3.3 RandD Costs Analysis 8.4 Alternative Product Analysis 8.5 Major Distributors of Stem Cell Therapy Analysis 8.6 Major Downstream Buyers of Stem Cell Therapy Analysis 8.7 Impact of COVID-19 and the Russia-Ukraine war on the Upstream and Downstream in the Stem Cell Therapy Industry

9 Players Profiles 9.1 Pharmicell Co., Ltd 9.1.1 Pharmicell Co., Ltd Basic Information, Manufacturing Base, Sales Region and Competitors 9.1.2 Stem Cell Therapy Product Profiles, Application and Specification 9.1.3 Pharmicell Co., Ltd Market Performance (2017-2022) 9.1.4 Recent Development 9.1.5 SWOT Analysis 9.2 MEDIPOST Co., Ltd. 9.2.1 MEDIPOST Co., Ltd. Basic Information, Manufacturing Base, Sales Region and Competitors 9.2.2 Stem Cell Therapy Product Profiles, Application and Specification 9.2.3 MEDIPOST Co., Ltd. Market Performance (2017-2022) 9.2.4 Recent Development 9.2.5 SWOT Analysis 9.3 Nuvasive, Inc. 9.3.1 Nuvasive, Inc. Basic Information, Manufacturing Base, Sales Region and Competitors 9.3.2 Stem Cell Therapy Product Profiles, Application and Specification 9.3.3 Nuvasive, Inc. Market Performance (2017-2022) 9.3.4 Recent Development 9.3.5 SWOT Analysis 9.4 RTI Surgical, Inc. 9.4.1 RTI Surgical, Inc. Basic Information, Manufacturing Base, Sales Region and Competitors 9.4.2 Stem Cell Therapy Product Profiles, Application and Specification 9.4.3 RTI Surgical, Inc. Market Performance (2017-2022) 9.4.4 Recent Development 9.4.5 SWOT Analysis 9.5 Holostem Terapie Avanzate S.r.l. 9.5.1 Holostem Terapie Avanzate S.r.l. Basic Information, Manufacturing Base, Sales Region and Competitors 9.5.2 Stem Cell Therapy Product Profiles, Application and Specification 9.5.3 Holostem Terapie Avanzate S.r.l. Market Performance (2017-2022) 9.5.4 Recent Development 9.5.5 SWOT Analysis 9.6 Cytori Therapeutics 9.6.1 Cytori Therapeutics Basic Information, Manufacturing Base, Sales Region and Competitors 9.6.2 Stem Cell Therapy Product Profiles, Application and Specification 9.6.3 Cytori Therapeutics Market Performance (2017-2022) 9.6.4 Recent Development 9.6.5 SWOT Analysis 9.7 Fibrocell Science, Inc. 9.7.1 Fibrocell Science, Inc. Basic Information, Manufacturing Base, Sales Region and Competitors 9.7.2 Stem Cell Therapy Product Profiles, Application and Specification 9.7.3 Fibrocell Science, Inc. Market Performance (2017-2022) 9.7.4 Recent Development 9.7.5 SWOT Analysis 9.8 Osiris Therapeutics, Inc. 9.8.1 Osiris Therapeutics, Inc. Basic Information, Manufacturing Base, Sales Region and Competitors 9.8.2 Stem Cell Therapy Product Profiles, Application and Specification 9.8.3 Osiris Therapeutics, Inc. Market Performance (2017-2022) 9.8.4 Recent Development 9.8.5 SWOT Analysis 9.9 Promethera Biosciences 9.9.1 Promethera Biosciences Basic Information, Manufacturing Base, Sales Region and Competitors 9.9.2 Stem Cell Therapy Product Profiles, Application and Specification 9.9.3 Promethera Biosciences Market Performance (2017-2022) 9.9.4 Recent Development 9.9.5 SWOT Analysis 9.10 RTI Surgical, Inc 9.10.1 RTI Surgical, Inc Basic Information, Manufacturing Base, Sales Region and Competitors 9.10.2 Stem Cell Therapy Product Profiles, Application and Specification 9.10.3 RTI Surgical, Inc Market Performance (2017-2022) 9.10.4 Recent Development 9.10.5 SWOT Analysis 9.11 Celgene Corporation 9.11.1 Celgene Corporation Basic Information, Manufacturing Base, Sales Region and Competitors 9.11.2 Stem Cell Therapy Product Profiles, Application and Specification 9.11.3 Celgene Corporation Market Performance (2017-2022) 9.11.4 Recent Development 9.11.5 SWOT Analysis 9.12 Anterogen Co., Ltd. 9.12.1 Anterogen Co., Ltd. Basic Information, Manufacturing Base, Sales Region and Competitors 9.12.2 Stem Cell Therapy Product Profiles, Application and Specification 9.12.3 Anterogen Co., Ltd. Market Performance (2017-2022) 9.12.4 Recent Development 9.12.5 SWOT Analysis

10 Research Findings and Conclusion

11 Appendix 11.1 Methodology 11.2 Research Data Source

Purchase this report (Price 3250 USD for a single-user license) https://www.360researchreports.com/purchase/21612397

About Us:

Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided todays businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors. 360 Research Reports is the credible source for gaining the market reports that will provide you with the lead your business needs.

Contact Us: Web : https://360researchreports.com/ Email: [emailprotected] Organization: 360 Research Reports Phone: +44 20 3239 8187/ +14242530807

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Stem Cell Therapy Market with 8.18% CAGR : Industry Analysis By Future Demand, Top Players, Revenue and Growth Rate Through 2027 | 112 Report Pages

See original here:
Stem Cell Therapy Market with 8.18% CAGR : Industry Analysis By Future Demand, Top Players, Revenue and Growth Rate Through 2027 | 112 Report Pages -...

Jcr Pharmaceuticals Co., Ltd. and Sysmex Establish A Joint Venture in the Field of Regenerative Medicine and Cell Therapy – Marketscreener.com

By Stem Cell Medicine

JCR Pharmaceuticals Co., Ltd. and Sysmex Corporation announced that they have established a joint venture (hereafter the "joint venture") for carrying out research and development, manufacture and sales of cell-based regenerative medicine products including hematopoietic stem cells and other stem cells. In recent years, the significant potential of regenerative medicine and cell therapy have been established in particular in areas that have traditionally been difficult to address with conventional chemically synthesized low molecular weight drugs1 or biopharmaceuticals2, such as the restoration of tissues and functions lost as a result of aging, illness, autoimmune diseases, or cancer. In particular, research and development on the therapeutic application of stem cells including hematopoietic stem cells, mesenchymal stem cells, and iPS cells have generated significant attention. Since its inception, JCR has been engaged in the research, development, manufacturing and sales of pharmaceutical products using regenerative medicine, genetic engineering, and gene therapy technologies to advance therapies in the rare disease field. This is exemplified in the field of regenerative medicine, by the approval of TEMCELL HS Inj.3, the first allogeneic regenerative medicine in Japan (Non-proprietary name: Human (allogeneic) bone marrow-derived mesenchymal stem cells) in February 2016 for the treatment of acute graft-versus-host disease (acute GVHD)4, a serious complication that develops after hematopoietic stem cell transplantation. In recent years, JCR has further streamlined and integrated its expertise around the establishment of groundbreaking medicines for the advancement of highly innovative medicines that could not be developed without such groundbreaking technologies. In the joint venture, the two companies aim to realize the social implementation of regenerative medicine and cell therapy by integrating JCR's expertise in developing, manufacturing and marketing regenerative medicine products, with Sysmex's expertise in quality control testing technology and knowledge of workflows efficiency using robotics technology, including IoT. AlliedCel Corporation, which is the corporate name of the joint venture following prior discussions regarding the alliance both companies, was established on October 3, 2022. The joint venture will advance programs of the potential for technology development and commercialization, including the project currently being promoted by both companies using hematopoietic stem cell proliferation technology. The name AlliedCel stands for the joint venture's aspiration to integrate knowledge and expertise from a broad set of collaborators and stakeholders including business partners, patients and their families, with the united goal of unleashing the power of cells in supporting patients in their need for life-changing therapies. Through the research and development of regenerative medicine products using diverse cells such as stem cells, AlliedCel aims to provide appropriate treatment options to patients and improve their prognosis.

View post:
Jcr Pharmaceuticals Co., Ltd. and Sysmex Establish A Joint Venture in the Field of Regenerative Medicine and Cell Therapy - Marketscreener.com

ANDREWS MEDICINE AND CELLTEX THERAPEUTICS CORPORATION JOIN FORCES TO BRING CUTTING EDGE TECHNOLOGIES TO ATHLETIC INJURIES – PR Newswire

By Stem Cell Medicine

HOUSTON, Oct. 4, 2022 /PRNewswire/ -- James R. "Jim" Andrews, MD, Chairman and CEO of Andrews Medicine of Pensacola, Florida, and David G. Eller, Chairman and CEO of Celltex Therapeutics Corporation of Houston, Texas, announced today that together they will form a new biotechnology company to bridge the divide between stem cell research and the current treatment of athletic injuries. The jointly owned company will operate under the name of "Andrews Celltex Biologics".

The new company will undertake the operation of a Sports Injury Program that includes the Celltex-sponsored FDA developmental study associated with its Investigational New Drug (IND) for the use of Celltex-produced autologous Mesenchymal Stem Cells (MSCs) in the treatment of orthopedic indications. Andrews Medicine will participate in this FDA observed IND research study and will be responsible for selection of participants and administration for this new study. The new venture promises to bring the best medical orthopedic practices of Andrews Medicine for treatment of sports injuries with best practices of Celltex for production of therapeutic quality autologous MSCsas a regenerative component of the treatment. Andrews Celltex Biologics will break new ground with this combined effort. The goal is an FDA approved Biologic License for this Celltex product.

Dr. Andrews said: "I have always known that stem cells, when properly handled, can add value to already effective treatments of inflammatory conditions caused by injury or disease. I am delighted that the FDA has been working with Celltex for studying the safety and efficacy of this combination of Celltex-produced MSCs with traditional medical treatment of multiple sports injury indications. Our know-how and network of sports teams and physicians will add immediate value to our new joint company. I am convinced that Andrews Celltex Biologics will be a leader in this huge growth sector of health care coupled with regenerative medicine."

"Celltex is excited about the opportunity to join forces with one of the best orthopedic and sports medicine companies in the country," said David G. Eller, Chairman and CEO of Celltex. "It is a perfect match. Surgical treatments coupled with Celltex-produced regenerative MSCs will improve recovery time and remediation. This joint effort of the two leading companies in their field will bring cutting edge regenerative health care for sports injuries and beyond."

David Eller continued, "Over the past 11 years, Celltex has developed unique know-how and proprietary technology to produce, in its specially designed cGMP lab, millions of MSCs from a small extraction of a person's adipose tissue. The integrity and vibrancy of the MSCs are of therapeutic quality. Over one trillion MSCs have been produced by Celltex, in its cGMP lab, from individuals wanting their own stem cells reintroduced into their bodies by medical doctors to fight a variety of diseases, especially those caused by inflammatory conditions. Given the autologous nature of Celltex-produced stem cells, there have been no severe adverse events when these stem cells have been reintroduced into the individuals from whom the small, one-time adipose tissue sample had been extracted."

ABOUT ANDREWS MEDICINE OF PENSACOLA, FLORIDA

Andrews Medicine is an integrated healthcare platform built on five decades of research, innovation, and clinical expertise led by internationally recognized orthopaedic surgeon, Dr. James "Jim" Andrews. Widely known as the surgeon for elite athletes from around the world, Dr. Andrews is also a pioneering thought leader in the field of research, injury prevention, new surgical techniques, and practice management. Andrews Medicine brings this experience and expertise to healthcare systems, medical providers, sports organizations, and the communities they serve, ensuring that every patient has access to exceptional clinical care. Read more at: http://www.andrewsmedicine.com

ABOUT CELLTEX THERAPEUTICS CORPORATION

Founded in 2011, Celltex Therapeutics Corporation is a Houston, Texas-based biotechnology company that specializes in the manufacturing and cryopreservation of Mesenchymal Stem Cells (MSCs).Celltex is a leading commercial provider of autologous MSCs for therapeutic use. The Company uses its proprietary technology to isolate, cryopreserve and culture billions of undifferentiated and genetically stable MSCs in its state-of-the-art current Good Manufacturing Practices (cGMP)-compliant laboratory.The Company is dedicated to pioneering technological breakthroughs in regenerative medicine. For more information see: http://www.celltexbank.com

SOURCE Celltex Therapeutics Corporation

Originally posted here:
ANDREWS MEDICINE AND CELLTEX THERAPEUTICS CORPORATION JOIN FORCES TO BRING CUTTING EDGE TECHNOLOGIES TO ATHLETIC INJURIES - PR Newswire

Regenerative Medicine For Heart Diseases: How It Is Better Than Conventional Treatments | TheHealthSite.co – TheHealthSite

By Stem Cell Medicine

The future possibilities of regenerative Medicine are endless. Know how regenerative medicine for heart diseases is better than conventional treatments.

Written by Longjam Dineshwori | Updated : October 5, 2022 9:52 AM IST

In the past few days, news of people dying due to cardiac arrest and heart attack during the festivities have been making headlines. Concerningly, increasing number of younger people, precisely adults who are in their 30s, are getting heart problems today. Health experts have been advising people to maintain a healthy lifestyle to prevent heart diseases or at least delay their onset. Also, tremendous advancements have been made in the field of cardiology making treatment of heart ailments more effective and less invasive. One of them is regenerative medicine, which is now being explored for the treatment of several diseases.

Get to more about regenerative medicine and its possibilities for treating heart diseases from Dr Pradeep Mahajan, Regenerative Medicine Researcher, Stem Rx Bioscience Solutions Pvt. Ltd, Navi Mumbai.

An alarming one out of four deaths in our country today is due to heart disease. This is largely due to our sedentary lifestyles, unhealthy eating habits, and stress. Barring the heart conditions that are present from birth (congenital) or that are passed down through the generations (inherited), heart diseases can be prevented or at least the onset can be delayed by maintaining a healthy lifestyle.

The field of cardiology (relating to the heart) has advanced tremendously, and there are several medications and surgical procedures that help patients maintain the functions of the heart. However, these call for invasive treatments and the need for life-long medications. Moreover, the side effects of medicines should also be taken into account.

Enter the field of Regenerative Cardiology! As the word suggests, this branch refers to utilising the natural healing potential of the body to repair and re-grow damaged heart tissues. Stem cells have been researched in several heart diseases to overcome the damage to the heart and facilitate healing. Not just stem cells, but cell-based products like exosomes, molecular chaperones, growth factors etc. have shown promise as well. Do not think about the technicalities, all these molecules are present in our body and researchers and clinicians are now working on how to apply these for the treatment of several diseases.

Commonly, we hear of blocks in the heart, infection, and weak muscles of the heart that do not pump blood properly leading to various diseases. With cell-based therapies, we can tackle each of these issues. Stem cells (the most basic 'unspecialized' cells of our body) can multiply and form various cells of the body, including heart cells. Similarly, cell products like exosomes are cargo packets they carry the required substances for repair and re-growth of tissues. These biological molecules have 'housekeeping functions, meaning that they ensure that any unwanted product and even bacteria/viruses are removed periodically from the body.

The possibilities of Regenerative Medicine for heart diseases are many blocks in the heart can be dissolved, blood supply can be improved, heart muscles can be strengthened, etc. because these biological molecules are capable of reducing inflammation (swelling) in the body, modify the immune system to function better, enhance the functions of other cells, etc. Since these are part of our own body, providing these molecules in the appropriate quantity at the desired site will enhance healing without side effects. In fact, there is ongoing research on growing healthy heart tissue in labs with these biological molecules to transplant them into the human body. Who knows, someday the whole heart might be grown in a lab! While the future possibilities are endless, the current cell-based therapies can be a definitive addition to enhance the outcomes of existing conventional treatments. Of course, rehabilitation and lifestyle modifications are mandatory to maintain the results.

A holistic approach is important one cannot simply rely on symptom management the core issues have to be targeted and Regenerative Medicine can do just that. The death rate due to heart disease can be reduced and patients will be able to have a better quality of life.

Follow us on

More:
Regenerative Medicine For Heart Diseases: How It Is Better Than Conventional Treatments | TheHealthSite.co - TheHealthSite

→←